TuHURA Wins U.S. Patent for Cancer Drug TBS-2025
Tampa, Florida, United States, October 13, 2026 TuHURA Biosciences, Inc., a clinical-stage immuno-oncology company, has received a new U.S....
Vaccines, Blood & Biologics
Zydus and Formycon Advance Keytruda Biosimilar FYB206
Ahmedabad, India, and Planegg-Martinsried, Germany, October 13, 2026 Zydus Lifesciences Limited and Formycon AG have announced that the U.S....
Scinai Signs $5.1M Oncology Drug Manufacturing Agreement
Jerusalem, Israel, October 13, 2026 Scinai Immunotherapeutics Ltd. has announced a definitive agreement through its wholly owned subsidiary, Scinai...
Jocasta and Diamond Target Cognitive Decline With New Drugs
Scottsdale, Arizona, United States, October 13, 2026 Jocasta Neuroscience and Diamond Therapeutics have entered into a joint research agreement...
Akiram Shares First Phase 1 Data for Cancer Drug AKIR001
Uppsala, Sweden, October 13, 2026 Akiram Therapeutics, a Swedish clinical-stage biotechnology company specializing in targeted molecular radiotherapy, has announced...
Merck Reports One-Year Results for Remigromig in DME
New Orleans, Louisiana, U.S., October 10, 2026 Merck has presented encouraging one-year results from the pivotal Phase 2b/3 BRUNELLO...
Racura Oncology Advances RC220 to 100 mg/m² in Lung Cancer
Sydney, Australia, October 12, 2026 Racura Oncology Limited has received clearance to advance its investigational cancer therapy RC220 to...
REGENXBIO Highlights Surabgene Lomparvovec in New Event
Rockville, Maryland, U.S., October 13, 2026 REGENXBIO Inc. has announced plans to host an investor event highlighting surabgene lomparvovec...
AstraZeneca Reports HICKORY Trial Results for HPP Drug
Cambridge, United Kingdom, October 12, 2026 AstraZeneca has announced results from the Phase III HICKORY clinical trial evaluating efzimfotase...
Blue Lake Biotechnology to Present BLB201 RSV Vaccine Data
Pittsburgh, Pennsylvania, U.S., October 12, 2026 Blue Lake Biotechnology, Inc. has announced that it will present new data for...